Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

704.31
+10.811.56%
Post-market: 705.000.6900+0.10%19:12 EST
Volume:1.13M
Turnover:799.18M
Market Cap:74.02B
PE:16.93
High:711.88
Open:693.34
Low:692.29
Close:693.50
52wk High:800.99
52wk Low:476.49
Shares:105.10M
Float Shares:103.30M
Volume Ratio:1.04
T/O Rate:1.10%
Dividend:2.64
Dividend Rate:0.37%
EPS(TTM):41.59
EPS(LYR):40.90
ROE:15.19%
ROA:6.16%
PB:2.39
PE(LYR):17.22

Loading ...

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
2 hours ago

BUZZ-Formycon up after it unveils development of biosimilar candidate for Dupixent

Reuters
·
Yesterday

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2025-11-13

Reuters
·
Nov 14

REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?

TIPRANKS
·
Nov 13

Regeneron Unveils Positive Data for Lynozyfic in Newly Diagnosed Multiple Myeloma at ASH 2025

Reuters
·
Nov 13

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

GlobeNewswire
·
Nov 13

Scotiabank Initiates Regeneron Pharmaceuticals at Sector Perform With $650 Price Target

MT Newswires Live
·
Nov 13

Formycon AG reports €19.5 million revenue for first nine months of 2025

Reuters
·
Nov 13

UK Court Backs Alvotech in Eylea Biosimilar Manufacturing Dispute

Reuters
·
Nov 13

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Nov 13

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2025-11-11

Reuters
·
Nov 12

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Benzinga_recent_news
·
Nov 11

Regeneron VP Controller Jason Pitofsky Reports Disposal of Common Shares

Reuters
·
Nov 11

Merck's Heart Pill Slashes Cholesterol Levels in Test Patients -- Barrons.com

Dow Jones
·
Nov 11

BRIEF-UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea

Reuters
·
Nov 10

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor Xi Antibodies Presented at American Heart Association Scientific Sessions and Published in the Lancet

THOMSON REUTERS
·
Nov 08

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Reuters
·
Nov 08

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Nov 08

Regeneron Pharma Is Maintained at Neutral by UBS

Dow Jones
·
Nov 08

UBS Adjusts Price Target on Regeneron Pharmaceuticals to $660 From $595, Maintains Neutral Rating

MT Newswires Live
·
Nov 08